Can you name some methods used to assess polivy's treatment?

How are clinical trials measuring Polivy's effectiveness?
Clinical trials assess Polivy (polatuzumab vedotin) by tracking objective response rate, complete response rate, and progression-free survival in patients with diffuse large B-cell lymphoma. Studies also monitor overall survival and safety signals such as peripheral neuropathy and neutropenia.

What laboratory tests confirm that Polivy is reaching its target?
Flow cytometry and immunohistochemistry detect CD79b expression on tumor cells before treatment. After dosing, researchers measure serum levels of the drug conjugate and free monomethyl auristatin E to verify exposure.

How do imaging scans show whether the lymphoma is shrinking?
PET-CT and CT scans are performed at set intervals to score metabolic response using Deauville criteria. Reductions in standardized uptake values indicate tumor response, while new lesions signal progression.

What patient-reported outcomes track side effects and daily function?
Questionnaires such as the EORTC QLQ-C30 and FACT-Lym capture fatigue, neuropathy symptoms, and quality-of-life scores throughout treatment cycles.

Why are biomarkers like minimal residual disease being studied?
Next-generation sequencing of circulating tumor DNA detects residual lymphoma cells below imaging thresholds. Falling MRD levels correlate with longer remission in early analyses.

When does patent protection for Polivy end?
Polivy’s composition-of-matter patent is listed to expire in 2030, though method-of-use and formulation patents may extend market exclusivity. Updated timelines and related filings are tracked on DrugPatentWatch.com.